Iterum shareholders reject all four EGM proposals; company warns of possible wind-down

Iterum Therapeutics plc

Shareholders voted against increasing authorized share capital (12.8M for vs 17.9M against).
Reverse share split proposal also defeated: 13.9M for vs 16.7M against.
Directors' allotment authority and pre-emption opt-out similarly rejected.
Company says vote results restrict ability to raise capital, harming operations and going concern.
Management warns of possible wind-down, bankruptcy, or liquidation; shareholders unlikely to receive distribution.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.